Pfizer announced detailed results from the first 2 pivotal Phase 3 trials of the OCTAVE program evaluating oral tofacitinib 10mg twice daily in inducing remission in adults with moderately to severely ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results